XML 54 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Segment, Geographical and Other Revenue Information
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Segment, Geographical and Other Revenue Information Segment, Geographical and Other Revenue Information
Segment Information
We manage our business as two business segments: Performance Enzymes and Novel Biotherapeutics. Our chief operating decision maker ("CODM") is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for the Company.
We report corporate-related expenses such as legal, accounting, information technology, and other costs that are not otherwise included in our reportable business segments as "corporate costs." All items not included in income (loss) from operations are excluded from the business segments.
All of our long lived assets are located in the United States. We manage our assets on a total company basis, not by business segment, as the majority of our operating assets are shared or commingled. Our CODM does not review asset information by business segment in assessing performance or allocating resources, and accordingly, we do not report asset information by business segment.
Factors considered in determining the two reportable segments of the Company include the nature of business activities, the management structure directly accountable to our CODM for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors. Our CODM regularly reviews our segments and the approach provided by management for performance evaluation and resource allocation.
Operating expenses that directly support the segment activity are allocated based on segment headcount, revenue contribution or activity of the business units within the segments, based on the corporate activity type provided to the segment. The expense allocation excludes certain corporate costs that are separately managed from the segments. This provides the CODM with more meaningful segment profitability reporting to support operating decisions and allocate resources.
The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):
Year Ended December 31, 2022Year Ended December 31, 2021
Performance EnzymesNovel BiotherapeuticsTotalPerformance EnzymesNovel BiotherapeuticsTotal
Revenues:
Product revenue$116,676 $— $116,676 $70,657 $— $70,657 
Research and development revenue9,936 11,978 21,914 19,858 14,239 34,097 
Total revenues126,612 11,978 138,590 90,515 14,239 104,754 
Costs and operating expenses:
Cost of product revenue38,033 — 38,033 22,209 — 22,209 
Research and development (1)
25,786 49,770 75,556 23,140 30,219 53,359 
Selling, general and administrative(1)
14,724 2,421 17,145 12,105 2,755 14,860 
Restructuring charges1,708 966 2,674 — — — 
Total segment costs and operating expenses80,251 53,157 133,408 57,454 32,974 90,428 
Income (loss) from operations$46,361 $(41,179)5,182 $33,061 $(18,735)14,326 
Corporate costs (2)
(33,080)(32,201)
Depreciation and amortization(5,418)(3,215)
Loss before income taxes$(33,316)$(21,090)
(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.
(2) Corporate costs include unallocated selling, general and administrative expense and restructuring charges, interest income, and other income (expense), net.
Year Ended December 31, 2021Year Ended December 31, 2020
Performance EnzymesNovel BiotherapeuticsTotalPerformance EnzymesNovel BiotherapeuticsTotal
Revenues:
Product revenue$70,657 $— $70,657 $30,220 $— $30,220 
Research and development revenue19,858 14,239 34,097 17,886 20,950 38,836 
Total revenues90,515 14,239 104,754 48,106 20,950 69,056 
Costs and operating expenses:
Cost of product revenue22,209 — 22,209 13,742 — 13,742 
Research and development (1)
23,140 30,219 53,359 20,923 21,705 42,628 
Selling, general and administrative (1)
12,105 2,755 14,860 9,597 2,355 11,952 
Total segment costs and operating expenses57,454 32,974 90,428 44,262 24,060 68,322 
Income (loss) from operations$33,061 $(18,735)14,326 $3,844 $(3,110)734 
Corporate costs (2)
(32,201)(22,306)
Depreciation and amortization(3,215)(2,099)
Loss before income taxes$(21,090)$(23,671)
(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.
(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income (expense), net.

The following table provides stock-based compensation expense included in income (loss) from operations (in thousands):
Year Ended December 31,
202220212020
Performance Enzymes$6,035 $5,047 $3,296 
Novel Biotherapeutics903 1,100 768 
Corporate cost7,593 5,446 3,664 
Total$14,531 $11,593 $7,728 
Significant Customers
Customers that each accounted for 10% or more of our total revenues were as follows:
Percentage of Total Revenues
For the Year Ended December 31,
 202220212020
Customer A56 %33 %*
Customer B*11 %26 %
Customer C**19 %
Customer D**11 %
* Percentage was less than 10%
Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented are as follows:
 As of December 31,
 20222021
Customer A53 %62 %
Customer D10 %*
* Percentage was less than 10%
Geographical Information
Geographic revenues are identified by the location of the customer and consist of the following (in thousands):
 Year Ended December 31,
202220212020
Revenues
Americas$17,000 $23,481 $24,352 
EMEA56,540 20,187 19,257 
APAC65,050 61,086 25,447 
Total revenues$138,590 $104,754 $69,056 
Identifiable long-lived assets by location was as follows (in thousands):
 December 31,
 20222021
United States$61,877 $65,457 
Identifiable goodwill by reporting unit was as follows (in thousands):
December 31, 2022December 31, 2021
Performance EnzymesNovel BiotherapeuticsTotalPerformance EnzymesNovel BiotherapeuticsTotal
Goodwill$2,463 $778 $3,241 $2,463 $778 $3,241